← Back to Screener
Tevogen Bio Holdings Inc. Common Stock (TVGN)
Price$7.38
Favorite Metrics
Price vs S&P 500 (26W)-88.10%
Price vs S&P 500 (4W)31.89%
Market Capitalization$30.73M
All Metrics
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.10
Price vs S&P 500 (YTD)-59.55%
EPS (TTM)$-8.44
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-8.44
EPS (Annual)$-7.91
Cash / Share (Quarterly)$0.14
ROA (Last FY)-599.49%
EBITD / Share (TTM)$-8.08
Cash Flow / Share (Annual)$-3.08
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-133.32x
ROA (TTM)-610.38%
EPS Incl Extra (Annual)$-7.91
Current Ratio (Annual)0.22x
Quick Ratio (Quarterly)0.10x
3-Month Avg Trading Volume0.03M
52-Week Price Return-85.53%
Revenue / Employee (TTM)$0
52-Week High$75.50
EPS Excl Extra (Annual)$-7.91
26-Week Price Return-79.36%
Quick Ratio (Annual)0.10x
13-Week Price Return-53.58%
Current Ratio (Quarterly)0.22x
Enterprise Value$36.231
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.14
3-Month Return Std Dev111.65%
Net Income / Employee (TTM)$-1
Net Interest Coverage (Annual)-133.33x
EPS Basic Excl Extra (Annual)$-7.91
Receivables Turnover (TTM)0.00x
EPS Incl Extra (TTM)$-8.44
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-120.62%
Year-to-Date Return-55.41%
5-Day Price Return32.26%
EPS Normalized (Annual)$-7.91
ROA (5Y Avg)-296.98%
Month-to-Date Return63.27%
EBITD / Share (Annual)$-7.80
EPS Basic Excl Extra (TTM)$-8.44
Price vs S&P 500 (13W)-56.45%
Beta0.28x
Revenue / Share (TTM)$0.00
52-Week Low$4.14
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
2.17
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TVGNTevogen Bio Holdings Inc. Common Stock | — | — | — | — | $7.38 |
AMGNAmgen Inc | 5.21x | 9.95% | 73.30% | 2.93% | $355.30 |
GILDGilead Sciences Inc | 5.80x | 2.40% | 78.83% | 133.64% | $137.64 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $849.04 |
BNTXBioNTech SE American Depositary Share | 8.99x | -11.81% | 84.21% | — | $102.92 |
BIIBBiogen Inc. Common Stock | 2.63x | 2.22% | 75.69% | -18.77% | $177.35 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $53.72 |
NBIXNeurocrine Biosciences Inc | 4.68x | 21.45% | 98.18% | 2.31% | $133.25 |
EXELExelixis Inc | 5.02x | 6.85% | 96.39% | 31.10% | $44.89 |
TECHBio-Techne Corp. | 7.62x | 1.64% | 66.60% | -20.58% | $59.23 |
HALOHalozyme Therapeutics, Inc. | 5.88x | 37.55% | 83.62% | 22.89% | $69.29 |
About
Tevogen Bio Holdings is a clinical-stage immunotherapy company developing off-the-shelf T cell therapies. The company harnesses CD8+ cytotoxic T lymphocytes to create precision treatments for infectious diseases, cancers, and neurological disorders. Its platform is designed for broad use without requiring patient-specific customization.